Comparative Pharmacology
Head-to-head clinical analysis: ETHACRYNATE SODIUM versus FUROSEMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ETHACRYNATE SODIUM versus FUROSEMIDE.
ETHACRYNATE SODIUM vs FUROSEMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ethacrynate sodium inhibits the Na-K-2Cl cotransporter (NKCC2) in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to increased diuresis.
Furosemide is a loop diuretic that inhibits the Na-K-2Cl cotransporter in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium ions, leading to increased urine output.
50 mg intravenously once daily; may increase in increments of 25-50 mg as needed, maximum 200 mg/day.
Adults: 20-80 mg orally once or twice daily; IV/IM: 20-40 mg once or twice daily, may increase by 20-40 mg every 6-8 hours. Max dose: 600 mg/day.
None Documented
None Documented
Clinical Note
moderateFurosemide + Digoxin
"The risk or severity of adverse effects can be increased when Furosemide is combined with Digoxin."
Clinical Note
moderateFurosemide + Digitoxin
"The risk or severity of adverse effects can be increased when Furosemide is combined with Digitoxin."
Clinical Note
moderateFurosemide + Deslanoside
"The risk or severity of adverse effects can be increased when Furosemide is combined with Deslanoside."
Clinical Note
moderateFurosemide + Acetyldigitoxin
Terminal elimination half-life: 2-4 hours in normal renal function; prolonged to 20-30 hours in end-stage renal disease.
0.5-2 hours (terminal); prolonged in renal impairment (up to 9-24 hours) and hepatic cirrhosis (up to 2-4 hours).
Renal: approximately 30% unchanged; biliary/fecal: minor (less than 10%); majority metabolized to cysteine adducts excreted in urine.
Renal (50-80% unchanged; remainder as glucuronide metabolite); fecal (<2%).
Category C
Category A/B
Loop Diuretic
Loop Diuretic
"The risk or severity of adverse effects can be increased when Furosemide is combined with Acetyldigitoxin."